富马酸二甲酯治疗对复发缓解型多发性硬化症患者睡眠质量的影响:一项多中心意大利可穿戴追踪器研究

IF 2.5 Q2 CLINICAL NEUROLOGY
Giancarlo Comi, Letizia Leocani, Luigi Ferini-Strambi, Marta Radaelli, Gloria D Costa, Roberta Lanzillo, Giacomo Lus, Valentina Bianchi, Sebastiano Traccis, Fioravante Capone, Luigi Me Grimaldi, Giuseppe Salemi, Alessandra Cardillo, Valentina Zipoli
{"title":"富马酸二甲酯治疗对复发缓解型多发性硬化症患者睡眠质量的影响:一项多中心意大利可穿戴追踪器研究","authors":"Giancarlo Comi,&nbsp;Letizia Leocani,&nbsp;Luigi Ferini-Strambi,&nbsp;Marta Radaelli,&nbsp;Gloria D Costa,&nbsp;Roberta Lanzillo,&nbsp;Giacomo Lus,&nbsp;Valentina Bianchi,&nbsp;Sebastiano Traccis,&nbsp;Fioravante Capone,&nbsp;Luigi Me Grimaldi,&nbsp;Giuseppe Salemi,&nbsp;Alessandra Cardillo,&nbsp;Valentina Zipoli","doi":"10.1177/20552173221144229","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sleep disorders are common in patients with multiple sclerosis and have a bidirectional interplay with fatigue and depression.</p><p><strong>Objective: </strong>To evaluate the effect of treatment with oral dimethyl fumarate on the quality of sleep in relapsing-remitting multiple sclerosis.</p><p><strong>Methods: </strong>This was a multicentre observational study with 223 relapsing-remitting multiple sclerosis subjects starting treatment with dimethyl fumarate (<i>n</i>=177) or beta interferon (<i>n</i>=46). All patients underwent subjective (Pittsburgh Sleep Quality Index) and objective (wearable tracker) measurements of quality of sleep. Fatigue, depression, and quality of life were also investigated and physical activity was monitored.</p><p><strong>Results: </strong>Patients treated with dimethyl fumarate had significant improvement in the quality of sleep as measured with the Pittsburgh Sleep Quality Index (<i>p</i><0.001). At all-time points, no significant changes in Pittsburgh Sleep Quality Index score were observed in the interferon group. Total and deep sleep measured by wearable tracker decreased at week 12 with both treatments, then remained stable for the total study duration. Depression significantly improved in patients treated with dimethyl fumarate. No significant changes were observed in mobility, fatigue and quality of life.</p><p><strong>Conclusion: </strong>In patients with relapsing-remitting multiple sclerosis, the treatment with dimethyl fumarate was associated with improvements in patient-reported quality of sleep. Further randomised clinical trials are needed to confirm the benefits of long-term treatment with dimethyl fumarate.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/f2/10.1177_20552173221144229.PMC9912562.pdf","citationCount":"1","resultStr":"{\"title\":\"Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.\",\"authors\":\"Giancarlo Comi,&nbsp;Letizia Leocani,&nbsp;Luigi Ferini-Strambi,&nbsp;Marta Radaelli,&nbsp;Gloria D Costa,&nbsp;Roberta Lanzillo,&nbsp;Giacomo Lus,&nbsp;Valentina Bianchi,&nbsp;Sebastiano Traccis,&nbsp;Fioravante Capone,&nbsp;Luigi Me Grimaldi,&nbsp;Giuseppe Salemi,&nbsp;Alessandra Cardillo,&nbsp;Valentina Zipoli\",\"doi\":\"10.1177/20552173221144229\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Sleep disorders are common in patients with multiple sclerosis and have a bidirectional interplay with fatigue and depression.</p><p><strong>Objective: </strong>To evaluate the effect of treatment with oral dimethyl fumarate on the quality of sleep in relapsing-remitting multiple sclerosis.</p><p><strong>Methods: </strong>This was a multicentre observational study with 223 relapsing-remitting multiple sclerosis subjects starting treatment with dimethyl fumarate (<i>n</i>=177) or beta interferon (<i>n</i>=46). All patients underwent subjective (Pittsburgh Sleep Quality Index) and objective (wearable tracker) measurements of quality of sleep. Fatigue, depression, and quality of life were also investigated and physical activity was monitored.</p><p><strong>Results: </strong>Patients treated with dimethyl fumarate had significant improvement in the quality of sleep as measured with the Pittsburgh Sleep Quality Index (<i>p</i><0.001). At all-time points, no significant changes in Pittsburgh Sleep Quality Index score were observed in the interferon group. Total and deep sleep measured by wearable tracker decreased at week 12 with both treatments, then remained stable for the total study duration. Depression significantly improved in patients treated with dimethyl fumarate. No significant changes were observed in mobility, fatigue and quality of life.</p><p><strong>Conclusion: </strong>In patients with relapsing-remitting multiple sclerosis, the treatment with dimethyl fumarate was associated with improvements in patient-reported quality of sleep. Further randomised clinical trials are needed to confirm the benefits of long-term treatment with dimethyl fumarate.</p>\",\"PeriodicalId\":18961,\"journal\":{\"name\":\"Multiple Sclerosis Journal - Experimental, Translational and Clinical\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/f2/10.1177_20552173221144229.PMC9912562.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple Sclerosis Journal - Experimental, Translational and Clinical\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20552173221144229\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20552173221144229","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1

摘要

背景:睡眠障碍在多发性硬化症患者中很常见,并且与疲劳和抑郁有双向相互作用。目的:探讨口服富马酸二甲酯对复发缓解型多发性硬化症患者睡眠质量的影响。方法:这是一项多中心观察性研究,223名复发缓解型多发性硬化症患者开始接受富马酸二甲酯(n=177)或干扰素(n=46)治疗。所有患者均接受主观(匹兹堡睡眠质量指数)和客观(可穿戴跟踪器)睡眠质量测量。还调查了疲劳、抑郁和生活质量,并监测了身体活动。结果:用匹兹堡睡眠质量指数(匹兹堡睡眠质量指数)测量,富马酸二甲酯治疗的患者睡眠质量有显著改善。结论:在复发-缓解型多发性硬化症患者中,富马酸二甲酯治疗与患者报告的睡眠质量改善有关。需要进一步的随机临床试验来证实长期使用富马酸二甲酯治疗的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.

Background: Sleep disorders are common in patients with multiple sclerosis and have a bidirectional interplay with fatigue and depression.

Objective: To evaluate the effect of treatment with oral dimethyl fumarate on the quality of sleep in relapsing-remitting multiple sclerosis.

Methods: This was a multicentre observational study with 223 relapsing-remitting multiple sclerosis subjects starting treatment with dimethyl fumarate (n=177) or beta interferon (n=46). All patients underwent subjective (Pittsburgh Sleep Quality Index) and objective (wearable tracker) measurements of quality of sleep. Fatigue, depression, and quality of life were also investigated and physical activity was monitored.

Results: Patients treated with dimethyl fumarate had significant improvement in the quality of sleep as measured with the Pittsburgh Sleep Quality Index (p<0.001). At all-time points, no significant changes in Pittsburgh Sleep Quality Index score were observed in the interferon group. Total and deep sleep measured by wearable tracker decreased at week 12 with both treatments, then remained stable for the total study duration. Depression significantly improved in patients treated with dimethyl fumarate. No significant changes were observed in mobility, fatigue and quality of life.

Conclusion: In patients with relapsing-remitting multiple sclerosis, the treatment with dimethyl fumarate was associated with improvements in patient-reported quality of sleep. Further randomised clinical trials are needed to confirm the benefits of long-term treatment with dimethyl fumarate.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.70
自引率
0.00%
发文量
54
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信